Patents by Inventor Zhenfei NING

Zhenfei NING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTISPECIFIC ANTIBODIES AND USES THEROF
    Publication number: 20260201033
    Abstract: This disclosure relates to anti-CLEC5A (C-type lectin domain family 5 member A) antibodies, antigen-binding fragments thereof. This disclosure relates to an antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to a tumor associated antigen (TAA) and a second antigen-binding domain that specifically binds to CLEC5A, and an Fc region. The present invention also relates to an antibody or an antigen-binding fragment thereof, comprising a second antigen-binding domain that specifically binds to an autoimmune disease target and to CLEC5A, and an Fc region.
    Type: Application
    Filed: January 13, 2026
    Publication date: July 16, 2026
    Inventors: Jinze Li, Jianhui Zhou, Amy-Jo Casbon, Rachael Palmer, Zhenfei Ning, Jintao Feng, Vivekananda Kedage, Jie Hu, Zhentao Sheng, Ping Yuan, Su Huang, Martin Treder, Liying Xie, Jingying Xia, Xuejiao Yang
  • Antibody or chimeric antigen receptor which targets Claudin 18.2
    Patent number: 12312402
    Abstract: Disclosed are an antibody or an antigen binding fragment or chimeric antigen receptor thereof which binds to Claudin18.2, and a preparation method and a use. The chimeric antigen receptor sequentially comprises the antibody or the antigen binding fragment thereof which binds to the Claudin18.2 antigen, an extracellular hinge region, a transmembrane region and an intracellular signaling region. The antibody or the antigen binding fragment or chimeric antigen receptor thereof has stronger affinity and killing capability for cells secreting Claudin18.2, and a better tumor inhibiting effects.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: May 27, 2025
    Assignee: Shandong Boan Biotechnology Co., Ltd.
    Inventors: Deyong Song, Li Zhou, Chuangchuang Dong, Zhenfei Ning
  • ANTI-4-1-1BBXCCR8 ANTIBODIES AND USES THEREOF
    Publication number: 20250129174
    Abstract: This disclosure relates to an antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to 4-1BB and a second antigen-binding domain that specifically binds to CCR8.
    Type: Application
    Filed: September 25, 2024
    Publication date: April 24, 2025
    Inventors: Jinze Li, Martin Treder, Zhenfei Ning, Priti Singh, Jianhui Zhou, Zhentao Sheng, Jintao Feng
  • ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR WHICH TARGETS CLAUDIN 18.2
    Publication number: 20220204609
    Abstract: Disclosed are an antibody or an antigen binding fragment or chimeric antigen receptor thereof which binds to Claudin18.2, and a preparation method and a use. The chimeric antigen receptor sequentially comprises the antibody or the antigen binding fragment thereof which binds to the Claudin18.2 antigen, an extracellular hinge region, a transmembrane region and an intracellular signaling region. The antibody or the antigen binding fragment or chimeric antigen receptor thereof has stronger affinity and killing capability for cells secreting Claudin18.2, and a better tumor inhibiting effects.
    Type: Application
    Filed: May 28, 2020
    Publication date: June 30, 2022
    Inventors: Deyong SONG, Li ZHOU, Chuangchuang DONG, Zhenfei NING